Cardiology and Therapy最新文献

筛选
英文 中文
A Validated Transthyretin Amyloid Cardiomyopathy Claims-Based Coding Algorithm: ValidATTR-US. 一种基于转甲状腺素淀粉样蛋白心肌病索赔的有效编码算法:validatr - us。
IF 3.2
Cardiology and Therapy Pub Date : 2026-11-10 DOI: 10.1007/s40119-026-00484-2
John Isaiah Jimenez, Gracia Fahed, Nixuan Cai, Margarita Udall, Hiroki Kitakata, Kevin M Alexander
{"title":"A Validated Transthyretin Amyloid Cardiomyopathy Claims-Based Coding Algorithm: ValidATTR-US.","authors":"John Isaiah Jimenez, Gracia Fahed, Nixuan Cai, Margarita Udall, Hiroki Kitakata, Kevin M Alexander","doi":"10.1007/s40119-026-00484-2","DOIUrl":"https://doi.org/10.1007/s40119-026-00484-2","url":null,"abstract":"<p><strong>Introduction: </strong>Lack of a validated United States (US) claims-based method for identifying transthyretin amyloid cardiomyopathy (ATTR-CM) limits the reliability and comparability of real-world evidence. We developed and validated a US claims-based coding algorithm (ValidATTR-US) to identify patients with ATTR-CM.</p><p><strong>Methods: </strong>ValidATTR-US was developed by optimizing previously published algorithms using International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes and refining them using the STAnford Research Repository (STARR, claims/electronic health record-linked database; N = 61,908) to define the index cohort (n = 694). The Stanford ATTR-CM Patient Registry (N = 634) served as the validation cohort for cross-referencing the index cohort. Index cohort inclusion criteria were age ≥ 60 years at diagnosis and ≥ 2 ATTR-CM diagnosis codes (ICD-10-CM, E85.[0, 1, 2, 4, 82]) on separate days and ≥ 2 cardiac-related codes or ≥ 1 tafamidis claim. Exclusion criteria were multiple myeloma (C90), light chain amyloidosis (E85.81), hematopoietic stem cell transplantation (Z94.84), and organ-limited amyloidosis (E85.4) when co-occurring with cerebral amyloid angiopathy (I68.0), end-stage renal disease (N18.6), or skin disorders (L99). Performance metrics included accuracy ({true positives [TPs] + true negatives [TNs]}/total sample), specificity (TNs/{TNs + false positives [FPs]}), and sensitivity (TPs/{TPs + false negatives [FNs]}).</p><p><strong>Results: </strong>Accuracy was 99.51% (95% confidence interval [CI] 99.45-99.56%), specificity 99.70% (99.65-99.74%), and sensitivity 80.76% (77.47-83.76%) for detecting patients with ATTR-CM (TP, n = 512; TN, n = 61,092; FP, n = 182; FN, n = 122). Individual ICD-10-CM codes were strongly predictive of ATTR-CM case status (area under the curve [AUC] 0.84) and genotype classification (AUC 0.88).</p><p><strong>Conclusion: </strong>ValidATTR-US is the first US claims-based ATTR-CM coding algorithm validated against a clinically confirmed ATTR-CM registry. Broader application may improve identification of patients with ATTR-CM in real-world datasets and help characterize prevalence and treatment patterns. Graphical abstract available for this article.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Access Site, Frailty and Outcomes in Older Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. 急性冠脉综合征老年患者经皮冠状动脉介入治疗的血管通路部位、脆弱性和结局。
IF 3.2
Cardiology and Therapy Pub Date : 2026-11-05 DOI: 10.1007/s40119-026-00486-0
Ioannis Karalis, Constantinos Andreou, Maria Mouratidou, J Wouter Jukema
{"title":"Vascular Access Site, Frailty and Outcomes in Older Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes.","authors":"Ioannis Karalis, Constantinos Andreou, Maria Mouratidou, J Wouter Jukema","doi":"10.1007/s40119-026-00486-0","DOIUrl":"https://doi.org/10.1007/s40119-026-00486-0","url":null,"abstract":"<p><strong>Introduction: </strong>In older patients with acute coronary syndromes (ACS), frailty predicts adverse outcomes, but whether radial access retains its lower complication rate in patients with frailty is unknown. We examined outcomes by access site and frailty status and whether frailty modified the association between access site and outcomes.</p><p><strong>Methods: </strong>We retrospectively studied 227 consecutive patients aged ≥ 70 years, irrespective of frailty status, who underwent percutaneous coronary intervention for ACS at a single center between January 2014 and June 2016. Frailty was screened at admission with the Dutch safety management system (Veiligheidsmanagementsysteem [VMS]) frailty instrument (frailty: VMS score ≥ 1). Primary endpoints were 1-year all-cause mortality and a 30-day composite outcome of death, vascular complications, bleeding, re-infarction and stroke. Effect modification was tested with interaction terms.</p><p><strong>Results: </strong>Access was femoral in 122 (53.7%) and radial in 105 (46.3%) patients. Of the 222 patients with a VMS score, 78 (35.1%) met frailty criteria. The 30-day composite endpoint occurred in 18.9% of patients with femoral access versus 3.8% with radial access (odds ratio [OR] 0.17, 95% confidence interval [CI] 0.06-0.51); 1-year mortality was 12.3% versus 6.7%, respectively (p = 0.14). The composite OR for radial access was 0.14 (95% CI 0.03-0.65) without frailty and 0.24 (95% CI 0.05-1.21) with frailty (ratio of ORs 1.70, 95% CI 0.19-15.54, p-interaction = 0.64; for 1-year mortality 1.24, 95% CI 0.19-8.33, p-interaction = 0.82). Frailty was associated with longer hospital stay and higher 1-year mortality adjusted for access site (hazard ratio [HR] 2.35, 95% CI 1.01-5.43), but not after further adjustment for age (HR 1.56, 95% CI 0.64-3.76).</p><p><strong>Conclusion: </strong>Radial access was associated with markedly fewer early complications while frailty was associated with longer hospitalization and lower 1-year survival, largely explained by age. There was no statistically significant evidence of interaction between frailty and access site, although the interaction analysis was limited by the small number of events. These findings are to be considered hypothesis-generating.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congestion, Inflammation, and Renal Impairment Mediate the Association Between Cardiac Troponin and Mortality in Acute Heart Failure. 充血、炎症和肾功能损害介导心肌肌钙蛋白与急性心力衰竭死亡率之间的关系。
IF 3.2
Cardiology and Therapy Pub Date : 2026-11-02 DOI: 10.1007/s40119-026-00487-z
Pietro Scicchitano, Massimo Iacoviello, Gabriella Ricci, Daniele De Feo, Giovanni Di Rienzo, Vincenzo Massimo Bonfantino, Francesco Massari
{"title":"Congestion, Inflammation, and Renal Impairment Mediate the Association Between Cardiac Troponin and Mortality in Acute Heart Failure.","authors":"Pietro Scicchitano, Massimo Iacoviello, Gabriella Ricci, Daniele De Feo, Giovanni Di Rienzo, Vincenzo Massimo Bonfantino, Francesco Massari","doi":"10.1007/s40119-026-00487-z","DOIUrl":"https://doi.org/10.1007/s40119-026-00487-z","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiac troponin is recognized as a strong predictor of mortality in patients with acute heart failure (AHF). The aim of this study was to evaluate the prognostic impact of high-sensitivity cardiac troponin I (hs-cTnI) on mortality risk in patients with AHF in relation to inflammatory, congestion, and renal indices.</p><p><strong>Methods: </strong>We enrolled 431 patients (79 ± 10 years, 51% male) with AHF. At admission, hemodynamic congestion, inflammatory status, and renal function were assessed by means of brain natriuretic peptide (BNP, ng/l), high-sensitivity C-reactive protein (hs-CRP, mg/l), and estimated glomerular filtration rate (eGFR, ml/min), respectively. Mediation analyses were performed to assess the presence and magnitude of these components.</p><p><strong>Results: </strong>The cumulative incidence of mortality at 180-day follow-up was 36%. hs-cTnI significantly correlated with BNP (r = 0.28), hs-CRP (r = 0.31), and eGFR (r = - 0.23); these variables explained 18% of the overall variability in hs-cTnI. In univariate Cox regression analysis, hs-cTnI, hs-CRP, BNP, and eGFR were predictors of all-cause death. The association between hs-cTnI and mortality was largely mediated by inflammation, congestion, and renal function, which collectively explained 69% of the total effect. In multivariate analysis, only ln hs-CRP (HR: 1.21; 1.08-1.37), ln BNP (HR: 1.37; 1.09-1.74), and eGFR (HR: 0.99; 0.98-1.00) remained independent predictors of mortality.</p><p><strong>Conclusions: </strong>Elevated troponin levels in AHF might be influenced by the coexistence of systemic inflammation, hemodynamic congestion, and renal dysfunction. Therefore, circulating troponin in AHF may be considered an integrated biomarker reflecting multiple pathophysiological processes.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-Hospital and One-Year Outcomes After Percutaneous Coronary Intervention for Chronic Coronary Occlusion in Octogenarians. 经皮冠状动脉介入治疗80多岁慢性冠状动脉闭塞患者的住院和1年预后。
IF 3.2
Cardiology and Therapy Pub Date : 2026-10-25 DOI: 10.1007/s40119-026-00485-1
Danial Amoey, Karim Elbasha, Mohamed Samy, Martin Landt, Arief Kurniadi, Oleg Schiopu, Abdelhakim Allali, Mohammed Saad, Felix J Hofmann, Derk Frank, Ralph Toelg, Gert Richardt, Stephan Fichtlscherer, Holger Nef, Nader Mankerious
{"title":"In-Hospital and One-Year Outcomes After Percutaneous Coronary Intervention for Chronic Coronary Occlusion in Octogenarians.","authors":"Danial Amoey, Karim Elbasha, Mohamed Samy, Martin Landt, Arief Kurniadi, Oleg Schiopu, Abdelhakim Allali, Mohammed Saad, Felix J Hofmann, Derk Frank, Ralph Toelg, Gert Richardt, Stephan Fichtlscherer, Holger Nef, Nader Mankerious","doi":"10.1007/s40119-026-00485-1","DOIUrl":"https://doi.org/10.1007/s40119-026-00485-1","url":null,"abstract":"<p><strong>Introduction: </strong>Older patients often present with complex coronary artery disease alongside multiple comorbidities. There is limited data on the outcomes of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in octogenarians. We aim to investigate the in-hospital and 1-year outcomes following successful CTO-PCI in octogenarians.</p><p><strong>Methods: </strong>Consecutive patients who had successful CTO-PCI at a single center between 01.2017 and 12.2022 were divided into two groups: octogenarians (age ≥ 80 and < 90 years, n = 123) and a control group (age < 80 years, n = 612). Periprocedural complications, in-hospital major adverse cardiac and cerebrovascular events (MACCE), and 1-year target lesion failure (TLF) were investigated.</p><p><strong>Results: </strong>Octogenarians had a higher prevalence of arterial hypertension (96.7% vs. 91.2%, p = 0.036), atrial fibrillation (28.5% vs. 12.1%, p < 0.001), and chronic kidney disease (CKD) (34.1% vs. 16.5%, p < 0.001) compared to younger counterparts. The rate of failed CTO recanalization was higher in octogenarians (18.5% vs. 8.2%, p < 0.001). Incidence of in-hospital MACCE and periprocedural complications was comparable between the study groups, except for a numerically higher in-hospital mortality in octogenarians (2.4% vs. 0.8%, p = 0.114), and a higher incidence of contrast-induced nephropathy (CIN) (11.4% vs. 4.9%, p = 0.006). At 1 year, TLF did not differ significantly between the study arms (16.2% vs. 12.3%, aHR 1.52; CI 0.81-2.84, p = 0.191). Notably, higher cardiac mortality rates were observed in the octogenarian arm (7.6% vs. 2.7%, HR 2.82; CI 1.13-7.08, p = 0.027).</p><p><strong>Conclusion: </strong>Despite numerically higher in-hospital mortality in octogenarians, CTO-PCI in those patients was performed with comparable periprocedural, and acute adverse outcomes, as well as 1-year TLF, to their younger counterparts. Octogenarians remain inherently at a higher long-term mortality risk. Graphical Abstract available for this article.</p><p><strong>Clinicaltrials: </strong></p><p><strong>Gov identifier: </strong>NCT06957613 (retrospectively registered, 03/05/2025).</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Effectiveness of Mavacamten in Canada: Insights from the MAVEN Study. Mavacamten在加拿大的实际有效性:来自MAVEN研究的见解。
IF 3.2
Cardiology and Therapy Pub Date : 2026-10-22 DOI: 10.1007/s40119-026-00483-3
Michael R Ward, Andrew M Crean, Olivier Desplantie, Benjamin D Tyrrell, Stéphanie Corriveau, Florence Brellier, Kevin C Ong
{"title":"Real-World Effectiveness of Mavacamten in Canada: Insights from the MAVEN Study.","authors":"Michael R Ward, Andrew M Crean, Olivier Desplantie, Benjamin D Tyrrell, Stéphanie Corriveau, Florence Brellier, Kevin C Ong","doi":"10.1007/s40119-026-00483-3","DOIUrl":"https://doi.org/10.1007/s40119-026-00483-3","url":null,"abstract":"<p><strong>Introduction: </strong>Previous studies have demonstrated the efficacy and safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), primarily outside of Canada, with limited Canadian real-world data evidence. The MAVEN study aimed to describe the real-world effectiveness of mavacamten in Canadian patients with oHCM.</p><p><strong>Methods: </strong>This multi-center, retrospective physician survey of patient charts included 115 patients with oHCM who initiated mavacamten between January 2023 and November 2024 across five Canadian sites. Effectiveness was assessed by changes in clinical characteristics and outcomes, including New York Heart Association (NYHA) functional class, resting and Valsalva left ventricular outflow tract (rLVOT and vLVOT, respectively) gradients, and left ventricular ejection fraction (LVEF), from treatment initiation to the most recent available assessment.</p><p><strong>Results: </strong>Baseline demographic and clinical characteristics were consistent with previously published data (median age 63.0 years; 66.1% aged ≥ 60 years; 51.3% male, 48.7% female patients; 57.4% NYHA class II, 42.6% NYHA class III). Median baseline rLVOT and vLVOT gradients were 44.0 and 78.0 mmHg, respectively, and median LVEF was 65.0%. Overall, 72.7% of patients improved by ≥ 1 NYHA functional class. Median reductions in rLVOT and vLVOT gradients were - 25.5 (interquartile range [IQR]: - 61, - 8) mmHg and - 51.0 (IQR: - 83, - 24) mmHg, respectively, while median LVEF changed by - 3.0% (IQR: - 8, 0). Mavacamten was discontinued in 8.7% of patients, including 2.6% due to treatment-emergent adverse events. Reductions in LVEF < 50% were observed in 6.1% of patients, and no patient experienced an LVEF < 30%.</p><p><strong>Conclusions: </strong>In this first Canadian real-world study of mavacamten effectiveness, treatment was associated with improvements in symptoms and LVOT obstruction. Reductions in LVEF < 50% were observed in a minority of patients, with no cases of LVEF < 30%. Given the retrospective design and heterogeneous follow-up of this study, these findings should be interpreted cautiously. Graphical abstract available for this article.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VERINA: A Phase IV Prospective Multicenter Study of Vericiguat in Indian Patients with Worsening Heart Failure and Reduced Ejection Fraction. VERINA: Vericiguat在印度心力衰竭恶化和射血分数降低患者中的4期前瞻性多中心研究。
IF 3.2
Cardiology and Therapy Pub Date : 2026-10-20 DOI: 10.1007/s40119-026-00482-4
Sandeep Seth, Atul Abhyankar, Jabir Abdullakutty, Suvro Banerjee, Kamal Sharma, Vinod Vijan, Nirav Chandulal Bhalani, Vijay Kumar Chopra, Rakesh Kumar Aggarwal, Abraham Oomman, Sandeep Bansal, Rajendra Kumar Jain, Pravin Kahale, Priyanka Sodhi, Disha Gupta, Ashish Gawde
{"title":"VERINA: A Phase IV Prospective Multicenter Study of Vericiguat in Indian Patients with Worsening Heart Failure and Reduced Ejection Fraction.","authors":"Sandeep Seth, Atul Abhyankar, Jabir Abdullakutty, Suvro Banerjee, Kamal Sharma, Vinod Vijan, Nirav Chandulal Bhalani, Vijay Kumar Chopra, Rakesh Kumar Aggarwal, Abraham Oomman, Sandeep Bansal, Rajendra Kumar Jain, Pravin Kahale, Priyanka Sodhi, Disha Gupta, Ashish Gawde","doi":"10.1007/s40119-026-00482-4","DOIUrl":"https://doi.org/10.1007/s40119-026-00482-4","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with heart failure (HF) with reduced ejection fraction (HFrEF) remain at high risk of cardiovascular (CV) death and hospitalization following a worsening heart-failure event. Data on vericiguat, a prescription oral medication used to treat symptomatic chronic HF, in adult Indian patients are limited.</p><p><strong>Methods: </strong>Adults with chronic HFrEF and a worsening heart-failure event were enrolled in a prospective, multicenter, open-label, single-arm phase IV study design. Participants received vericiguat in addition to foundational medical therapy (FMT) and were followed for approximately 48 weeks. The primary endpoint was CV death or first hospitalization for HF. Secondary endpoints included CV death, first hospitalization for HF, all-cause death or first hospitalization for HF, all-cause death and safety outcomes.</p><p><strong>Results: </strong>Of 231 patients who underwent screening, 205 received vericiguat and comprised the safety analysis set; of these, 203 patients constituted the full analysis set. The mean age of participants was 58 years. Baseline use of angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter-2 inhibitors was 52.7% and 75.6%, respectively. At week 48, Kaplan-Meier (KM) estimates were 10.1% for the primary endpoint, 3.3% for CV death, 9.1% for first hospitalization for HF, 11.5% for all-cause death or first hospitalization for HF, and 5.9% for all-cause death. Attainment of the target dose was 91.6%, with 69.5% of participants reaching and maintaining 10 mg by week 4. Study drug-related adverse events (AEs) were reported in 3.4% of participants, and treatment-emergent AEs requiring discontinuation in 2.0% of participants.</p><p><strong>Conclusion: </strong>In Indian patients with worsening HFrEF, high target-dose attainment and no new safety signals were observed during 48 weeks of vericiguat treatment.</p><p><strong>Trial registration: </strong>Clinical Trials Registry-India: CTRI/2022/11/047636.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticoagulation in Mechanical Circulatory Support: Contemporary Challenges and Future Directions in Cardiovascular Pharmacotherapy. 机械循环支持中的抗凝:心血管药物治疗的当代挑战和未来方向。
IF 3.2
Cardiology and Therapy Pub Date : 2026-10-16 DOI: 10.1007/s40119-026-00480-6
Lama Alfehaid, Mansour Alomran, Ahlam Althobaiti, Abdulmajeed Alshehri, Reem Bahmaid, Arif Albulushi
{"title":"Anticoagulation in Mechanical Circulatory Support: Contemporary Challenges and Future Directions in Cardiovascular Pharmacotherapy.","authors":"Lama Alfehaid, Mansour Alomran, Ahlam Althobaiti, Abdulmajeed Alshehri, Reem Bahmaid, Arif Albulushi","doi":"10.1007/s40119-026-00480-6","DOIUrl":"https://doi.org/10.1007/s40119-026-00480-6","url":null,"abstract":"<p><p>Mechanical circulatory support (MCS) is increasingly used in patients with cardiogenic shock, advanced heart failure, and severe respiratory failure; however, anticoagulation management remains challenging due to the competing risks of thrombosis, bleeding, hemolysis, and device dysfunction. In this review, we synthesize contemporary evidence on anticoagulant selection, monitoring strategies, and device-specific management across major MCS platforms, including extracorporeal membrane oxygenation, temporary ventricular assist devices, Impella devices, and durable left ventricular assist devices. Unfractionated heparin remains the cornerstone anticoagulant across most MCS platforms, while anti-factor Xa-guided monitoring is increasingly incorporated into clinical practice in many centers alongside activated partial thromboplastin time and other monitoring modalities. Direct thrombin inhibitors represent important alternatives, particularly for patients with heparin-induced thrombocytopenia or heparin resistance. Recent advances include bicarbonate-based purge strategies for Impella support and evolving antithrombotic approaches in HeartMate 3 recipients, introduced by the ARIES-HM3 trial. Emerging investigational strategies, including direct oral anticoagulants, factor XI/XII inhibition, and precision anticoagulation approaches, show promise for improving hemocompatibility; however, current evidence remains limited, and further prospective studies are required before these strategies can be routinely adopted. Overall, contemporary evidence supports an individualized approach to anticoagulation based on device characteristics, patient-specific risk profiles, and current guideline recommendations, while highlighting important knowledge gaps that warrant further high-quality prospective investigation.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparative Evaluation of ChatGPT and Google Search Output for Caregiver Education in Tetralogy of Fallot. ChatGPT与谷歌搜索输出在法洛四联症护理者教育中的比较评价。
IF 3.2
Cardiology and Therapy Pub Date : 2026-10-07 DOI: 10.1007/s40119-026-00481-5
Shreyas V Menon, Armaun D Rouhi, Jason J Han
{"title":"A Comparative Evaluation of ChatGPT and Google Search Output for Caregiver Education in Tetralogy of Fallot.","authors":"Shreyas V Menon, Armaun D Rouhi, Jason J Han","doi":"10.1007/s40119-026-00481-5","DOIUrl":"https://doi.org/10.1007/s40119-026-00481-5","url":null,"abstract":"<p><strong>Introduction: </strong>Caregivers of children with tetralogy of Fallot (TOF) frequently seek medical information online to better understand their child's diagnosis, treatment, and long-term care. Recently, generative artificial intelligence (AI) tools, including Google AI Overview and ChatGPT, have emerged as widely accessible sources of health information. However, the quality, readability, and accuracy of these platforms for caregiver education in congenital heart disease remain poorly characterized.</p><p><strong>Methods: </strong>Forty frequently asked caregiver questions regarding TOF were identified using Google's \"People Also Ask\" feature. Each question was submitted to ChatGPT-5.5 and entered as a Google search query, generating 80 total responses. Google search output comprised 37 AI Overviews and three organic search excerpts. Responses were evaluated for word count, Flesch Reading Ease (FRE), and Flesch-Kincaid grade level (FKGL). Two independent reviewers assessed response accuracy using a 5-point Likert scale, while one reviewer evaluated educational quality using a modified Ensuring Quality Information for Patients (EQIP) instrument.</p><p><strong>Results: </strong>Compared with Google search output (37 AI Overviews and three organic search excerpts), ChatGPT-5.5 generated significantly longer responses (327.9 ± 117.0 vs. 192.5 ± 85.9 words, p < 0.001), with a higher reading level (FKGL: 23.7 ± 8.5 vs. 15.4 ± 3.6, p < 0.001) and lower readability (FRE: 17.3 ± 14.9 vs. 27.4 ± 11.7, p < 0.001). ChatGPT-5.5 demonstrated higher reviewer-rated accuracy (4.95 ± 0.19 vs. 4.40 ± 0.44, p < 0.001) and higher modified EQIP scores (86.44% ± 7.01% vs. 59.62% ± 13.99%, p < 0.001).</p><p><strong>Conclusions: </strong>Under the study's prompting conditions, ChatGPT-5.5 responses received higher reviewer-rated accuracy and modified EQIP scores than Google search output but were longer and had higher calculated reading-grade levels. These findings do not establish improved caregiver comprehension, which was not directly assessed.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Outcomes Among Adults with Type 2 Diabetes or Obesity Receiving Carbohydrate-Reduced Nutrition via Telemedicine: A Retrospective Claims-Based Cohort Study. 通过远程医疗接受碳水化合物减少营养的成人2型糖尿病或肥胖症患者的心血管结局:一项基于索赔的回顾性队列研究
IF 3.2
Cardiology and Therapy Pub Date : 2026-10-02 DOI: 10.1007/s40119-026-00478-0
Caroline G P Roberts, Priya V Shanmugam, Shaminie J Athinarayanan, Adam J Wolfberg, Stephen Raskin, Francisco Lopez-Jimenez
{"title":"Cardiovascular Outcomes Among Adults with Type 2 Diabetes or Obesity Receiving Carbohydrate-Reduced Nutrition via Telemedicine: A Retrospective Claims-Based Cohort Study.","authors":"Caroline G P Roberts, Priya V Shanmugam, Shaminie J Athinarayanan, Adam J Wolfberg, Stephen Raskin, Francisco Lopez-Jimenez","doi":"10.1007/s40119-026-00478-0","DOIUrl":"https://doi.org/10.1007/s40119-026-00478-0","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular (CV) risk factors improve with carbohydrate-reduced nutrition, but the impact on CV outcomes is unknown. We assessed the incidence of CV outcomes associated with a carbohydrate-reduced telemedicine intervention in a retrospective claims-based cohort study.</p><p><strong>Methods: </strong>Adults with type 2 diabetes or obesity receiving individualized nutritional therapy (INT) between January 1, 2016 and June 1, 2025, were compared with propensity score-matched controls. Primary outcomes included (1) 3-point major adverse CV events (MACE), defined as nonfatal myocardial infarction, nonfatal stroke, or death from any cause (MACE-3); (2) 6-point MACE, adding percutaneous coronary intervention, hospitalization for heart failure or unstable angina (MACE-6); (3) all new-onset CV disease (CVD) events; and (4) new-onset hypertension.</p><p><strong>Results: </strong>In 4877 participants in each cohort (mean age, 51 [SD 9.5] years; 2939 [60.3%] female), INT was associated with lower risk of all primary outcomes. Incidence per 1000 person-years was 4.1 vs. 9.3 for MACE-3, 5.7 vs. 10.8 for MACE-6, 27.7 vs. 36.9 for all new-onset CVD, and 41.8 vs. 49.3 for new-onset hypertension. Hazard ratios were 0.44 (95% CI, 0.29-0.65; P < 0.001) for MACE-3, 0.52 (95% CI, 0.37-0.73; P < 0.001) for MACE-6, 0.70 (95% CI, 0.59-0.82; P < 0.001) for all CVD, and 0.81 (95% CI, 0.70-0.93; P < 0.001) for new-onset hypertension.</p><p><strong>Conclusions: </strong>Individualized telemedicine nutrition therapy was associated with lower CV event incidence compared to controls, suggesting the intervention may confer cardioprotection.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT. 他法非地对转甲状腺素淀粉样心肌病患者转甲状腺素浓度的影响及其与全因死亡率的关系:atr - act分析。
IF 3.2
Cardiology and Therapy Pub Date : 2026-10-01 Epub Date: 2026-08-27 DOI: 10.1007/s40119-026-00468-2
Mathew S Maurer, Perry Elliott, Jeffery W Kelly, Mazen Hanna, Evan T Powers, Steve Riley, Rong Wang, Pablo Garcia-Pavia
{"title":"Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT.","authors":"Mathew S Maurer, Perry Elliott, Jeffery W Kelly, Mazen Hanna, Evan T Powers, Steve Riley, Rong Wang, Pablo Garcia-Pavia","doi":"10.1007/s40119-026-00468-2","DOIUrl":"10.1007/s40119-026-00468-2","url":null,"abstract":"<p><strong>Introduction: </strong>Tafamidis is approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM) on the basis of results of the phase 3 study ATTR-ACT. This post hoc analysis from ATTR-ACT evaluated the effect of tafamidis on transthyretin (TTR) concentration and explored the potential relationship between changes in TTR concentration at month 1 (early ΔTTR) and all-cause mortality (ACM).</p><p><strong>Methods: </strong>Patients with ATTR-CM treated with tafamidis 80 mg or placebo in ATTR-ACT who survived until month 1 were included. The independent association between early ΔTTR and ACM at month 30 was evaluated using univariate analyses, including a logistic model for ACM incidence and a Cox model for time to ACM. Baseline variables significantly influencing this relationship were identified using backward selection and included as covariates (baseline TTR concentration and National Amyloidosis Centre stage) in a multivariable Cox model.</p><p><strong>Results: </strong>Tafamidis 80 mg produced a 36.3% mean increase in TTR concentration by month 1 (mean [SD] change 7.3 [3.9] mg/dL) that was sustained through month 30, whereas placebo showed minimal change at month 1 (mean change [SD] - 0.02 [2.9] mg/dL) and throughout the study period. Logistic regression showed early ΔTTR was associated with reduced odds of ACM by month 30 only in patients treated with tafamidis; every 5 mg/dL increase correlated with a 45.0% reduction in odds of ACM (p = 0.0193). In univariate analysis, every 1 mg/dL increase in TTR concentration at month 1 in patients treated with tafamidis was associated with a 9.3% hazard reduction in ACM (hazard ratio 0.907; 95% CI 0.837-0.983, p = 0.0174). Multivariable analysis showed an 8.7% reduction in hazard of ACM for each 1 mg/dL increase.</p><p><strong>Conclusions: </strong>Tafamidis was associated with an early increase in TTR concentration that was sustained through month 30, and early increases correlated with reduced ACM. However, mechanisms underlying TTR concentration increases and their clinical significance remain unclear. Graphical abstract available for this article.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier NCT01994889.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":"1-18"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书